https://www.selleckchem.com/pr....oducts/ulixertinib-b
4 kPa [7.7-12.6]), compared with non-survivors (Sao 88% [80-92%]; Pao /Fio ratio 8.5 kPa [7.1-11.5]). Patients requiring ECMO because of asthma were more likely to survive (95% survival rate (95% CI, 91-99%), compared with a survival of 71% (95% CI, 69-74%) in patients with respiratory failure attributable to other diagnoses. A national ECMO service can achieve good short-term outcomes for patients with undifferentiated respiratory failure refractory to conventional management. NCT03979222. NCT03979222. Data on UK
Like
Comment
Share
